trial

Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females

NCTId NCT06590298
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Not Yet Recruiting
Enrollment 600 (estimated)
Sponsored by Universiti Putra Malaysia
Primary completion 2025-03-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Not Yet Recruiting
Enrollment
600 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2024-09-15
Primary completion
2025-03-15
Eligibility
FEMALE · 18 Years · 65 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Universiti Putra MalaysiaLead Sponsor

Investigators

1
MUHAMMAD ARSHED, PhDPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
600
Phase
PHASE4
Primary Completion Date
2025-03-15
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Universiti Putra Malaysia
company
indication
Weight Gain
indication
Psychosis
indication
Metabolic Syndrome
indication
investigator
MUHAMMAD ARSHED, PhD
person